Navigation Links
GenWay Clinical Laboratory receives accreditation from College of American Pathologists
Date:12/15/2009

GenWay Biotech, Inc. GenWay Clinical Laboratory, San Diego, California, has been awarded an accreditation by the College of American Pathologists (CAP), based on results of a recent onsite inspection.

The laboratory's director was advised of this national recognition and congratulated for the "excellence of the services being provided." GenWay Biotech Inc. GenWay Clinical Laboratory is one of nearly 7,000 CAP-accredited laboratories nationwide.

The CAP Laboratory Accreditation Program, begun in the early 1960s, is recognized by the federal government as being equal to or more stringent than the government's own inspection program.

During the CAP accreditation process, inspectors examine the laboratory's records and quality control of procedures for the preceding two years. CAP inspectors also examine the entire staff's qualifications, the laboratories equipment, facilities, safety program and record, as well as to the overall management of the laboratory. This stringent inspection program is designed to specifically ensure the highest standard of care for all laboratory patients.


'/>"/>

Contact: Sue Masaracchia-Roberts
800-323-4040 x7319
GenWay Biotech
Source:Eurekalert

Page: 1

Related biology news :

1. General tumor marker test now offered by GenWay clinical laboratory
2. GenWay Biotech obtains exclusive rights to AMDLs DR-70 cancer test in US and Canada
3. UAB bone center director wins distinguished service award from clinical pathology society
4. TNO and Seventh Wave sign letter of intent on joint preclinical pharmaceutical outsourcing services
5. Magnetic nanotags spot cancer in mice earlier than methods now in clinical use
6. RadMD reaches 150th clinical trial
7. New cancer drug test promises safer and more effective clinical trials
8. IRSF announces funding of first clinical trial with disease-modifying therapy for Rett syndrome
9. Neurimmune Therapeutics Announces Advancement of Alzheimers Program into Preclinical Development
10. Antibody targeting of glioblastoma shows promise in preclinical tests, say Lombardi researchers
11. $20 million NIH grant to transform clinical research at UIC
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/13/2016)...  IMPOWER physicians supporting Medicaid patients in ... standard in telehealth thanks to a new partnership with ... IMPOWER patients can routinely track key health measurements, such ... and, when they opt in, share them with IMPOWER ... local retail location at no cost. By leveraging this ...
(Date:3/31/2016)... -- Genomics firm Nabsys has completed a financial  restructuring under ... M.D., who returned to the company in October 2015. ... including Chief Technology Officer, John Oliver , Ph.D., ... Vice President of Software and Informatics, Michael Kaiser ... Bready served as CEO of Nabsys from 2005-2014 and ...
(Date:3/23/2016)... , March 23, 2016 ... erhöhter Sicherheit Gesichts- und Stimmerkennung mit Passwörtern ... (NASDAQ: MESG ), ein führender ... das Unternehmen mit SpeechPro zusammenarbeitet, um erstmals ... Finanzdienstleistungsbranche, wird die Möglichkeit angeboten, im Rahmen ...
Breaking Biology News(10 mins):
(Date:6/24/2016)... 24, 2016 Epic Sciences unveiled a ... susceptible to PARP inhibitors by targeting homologous recombination ... The new test has already been incorporated into ... cancer types. Over 230 clinical trials ... pathways, including PARP, ATM, ATR, DNA-PK and WEE-1. ...
(Date:6/24/2016)... ... 2016 , ... Researchers at the Universita Politecnica delle Marche in Ancona combed ... pleural mesothelioma. Their findings are the subject of a new article on the Surviving ... signposts in the blood, lung fluid or tissue of mesothelioma patients that can help ...
(Date:6/23/2016)... ... June 23, 2016 , ... UAS LifeSciences, one of the ... brand, UP4™ Probiotics, into Target stores nationwide. The company, which has been manufacturing ... to its list of well-respected retailers. This list includes such fine stores as ...
(Date:6/23/2016)... , June 23, 2016 /PRNewswire/ - FACIT has ... Ontario biotechnology company, Propellon Therapeutics Inc. ... and commercialization of a portfolio of first-in-class WDR5 ... targets such as WDR5 represent an exciting class ... in precision medicine for cancer patients. Substantial advances ...
Breaking Biology Technology: